NASDAQ$TVRD
Tvardi Therapeutics Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Reported financial results and operational highlights for the second quarter ended June 30, 2020.
Cara Therapeutics reported a net loss of $25.1 million and total revenue of $5.6 million for the three months ended June 30, 2020. The company is on track to submit its first New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the fourth quarter.
- Advanced clinical development programs for both KORSUVA™ Injection and Oral KORSUVA.
- Positive top-line data from KALM™-2 pivotal Phase 3 trial of KORSUVA Injection for chronic kidney disease-associated pruritus (CKD-aP) in hemodialysis patients.
- On track to submit first New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the fourth quarter.
- Successfully completed a planned interim statistical analysis of KARE Phase 2 dose-ranging trial of Oral KORSUVA for moderate-to-severe pruritus in atopic dermatitis (AD) patients and expect the trial to be fully enrolled by the fourth quarter.
Headline financials
Revenue & EPS history
Tvardi Therapeutics · Revenue · Quarterly
$5.63M
Revenue by segment
Tvardi Therapeutics · $8.1M total across 1 segment · Q1 2020
- Collaboration Revenue$8.1M—100.0%
Forward guidance
Cara expects that its existing cash and cash equivalents and available-for-sale marketable securities as of June 30, 2020 will be sufficient to fund its currently anticipated operating expenses and capital expenditures into the second half of 2021, without giving effect to any potential milestone payments under existing collaborations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
+1.4%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+0.6%
Avg return
30 days after
50%
24 / 48 earnings
Positive
+42.3%
Q3 2016
Best reaction
-34.9%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2024 | +5.0% | -2.5% | +11.3% | |
| Q3 2024 | -4.1% | -7.1% | -19.1% | |
| Q2 2024 | -3.9% | -4.1% | -22.2% | |
| Q1 2024 | +1.0% | +4.7% | -5.0% | |
| Q4 2023 | -4.2% | +3.3% | -4.5% | |
| Q3 2023 | +4.3% | +4.8% | +14.3% | |
| Q2 2023 | -6.1% | -1.9% | -31.0% | |
| Q1 2023 | +11.2% | -5.2% | -16.0% | |
| Q4 2022 | -34.9% | -41.1% | -54.2% | |
| Q3 2022 | +3.6% | +20.8% | +35.4% | |
| Q2 2022 | +4.8% | +2.1% | -2.8% | |
| Q1 2022 | +14.7% | +4.5% | +9.8% | |
| Q4 2021 | +11.2% | +3.2% | +17.2% | |
| Q3 2021 | +1.4% | -9.2% | -28.5% | |
| Q2 2021 | +1.6% | +8.4% | +21.6% | |
| Q1 2021 | +3.7% | +5.1% | +10.1% | |
| Q4 2020 | -7.4% | -4.6% | +1.6% | |
| Q3 2020 | +7.7% | +10.5% | +6.4% | |
| Q2 2020 | +2.8% | -3.9% | -8.0% | |
| Q1 2020 | +6.8% | +6.1% | +16.1% | |
| Q4 2019 | -5.2% | -6.4% | -20.6% | |
| Q3 2019 | -4.8% | +3.9% | -20.9% | |
| Q2 2019 | +8.2% | +3.6% | +6.0% | |
| Q1 2019 | -5.1% | -6.7% | -0.4% | |
| Q4 2018 | +13.7% | +7.2% | +13.7% | |
| Q3 2018 | +0.8% | +0.6% | -12.5% | |
| Q2 2018 | +6.0% | +9.6% | +11.3% | |
| Q1 2018 | -3.4% | +1.5% | +30.4% | |
| Q4 2017 | -9.2% | -15.0% | -10.1% | |
| Q3 2017 | +1.2% | +2.2% | +4.9% | |
| Q2 2017 | +22.9% | +8.1% | +4.5% | |
| Q1 2017 | -7.7% | -4.6% | +10.3% | |
| Q4 2016 | -12.3% | -10.9% | +4.1% | |
| Q3 2016 | +42.3% | +58.9% | +61.3% | |
| Q2 2016 | -1.5% | -0.7% | -12.5% | |
| Q1 2016 | -4.3% | — | — | |
| Q4 2015 | -3.8% | — | — | |
| Q3 2015 | +11.9% | — | — | |
| Q2 2015 | +4.0% | — | — | |
| Q1 2015 | -1.6% | — | — | |
| Q4 2014 | +10.2% | — | — | |
| Q3 2013 | -2.1% | — | — | |
| Q3 2014 | -2.1% | — | — | |
| Q2 2014 | -1.8% | — | — | |
| Q2 2013 | -1.8% | — | — | |
| Q1 2013 | -1.7% | — | — | |
| Q1 2014 | -1.7% | — | — | |
| Q4 2013 | -2.7% | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro